SWOG clinical trial number
S9809
The Effect of Fluoroquinolones on the Disease-Free Interval in Patients with Stage Ta Transitional Cell Carcinoma of the Bladder, Phase III
Closed
Phase
Accrual
13%
Published
Research committees
Genitourinary Cancer
Treatment
Cephalexin
Ciprofloxacin hydrochloride
Eligibility Criteria Expand/Collapse
Pts must have Stage Ta (any grade) transitional cell carcinoma of the bladder by cystoscopy (within 42 days). Pts w/ recurrent bladder disease must not have had a diagnosis greater than (or equal to) T2. Patients who are high risk for upper tract (ureter or renal/pelvic) transitional cell cancers are not eligible. Prior radiation therapy and/or intravesical therapy is allowed provided 28 days have elapsed and there are no toxicities. Pts must not be receiving hemo or peritoneal dialysis. Pts must not be allergic to fluoroquinolones. Pts must not be currently taking or have taken fluoroquinolone within 3 months of the cytoscopy. If pt allergic to penicillin or cephalosporin, pt must be able to take sulfamethoxazole/trimethoprim. Pts must not be currently taking probenecid or theophylline. All pts stratified as having recurrent disease must agree to submission of bladder washing samples (at time of TURBT).
Publication Information Expand/Collapse
2007
Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study [PMID17574960]
2003
Southwest Oncology Group studies in bladder cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase